Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free EDIT Stock Alerts

Editas Medicine (EDIT) Financials

Editas Medicine logo
$2.45 -0.30 (-10.91%)
Closing price 04:00 PM Eastern
Extended Trading
$2.52 +0.07 (+3.06%)
As of 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Editas Medicine

Annual Income Statements for Editas Medicine

This table shows Editas Medicine's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -73 -97 -120 -110 -134 -116 -193 -220 -153 -237 -160
Consolidated Net Income / (Loss)		 -73 -97 -120 -110 -134 -116 -193 -220 -153 -237 -160
Net Income / (Loss) Continuing Operations		 -73 -97 -120 -110 -134 -116 -192 -220 -153 -237 -160
Total Pre-Tax Income 		-73 -97 -120 -110 -134 -116 -193 -220 -153 -237 -160
Total Operating Income		 -35 -97 -120 -114 -141 -135 -193 -226 -169 -251 -160
Total Gross Profit		 1.63 6.05 14 0.00 21 91 0.00 20 78 0.00 41
Total Revenue		 1.63 6.05 14 0.00 21 91 0.00 20 78 0.00 41
Operating Revenue		 1.63 6.05 14 0.00 21 91 0.00 20 78 0.00 41
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 37 103 134 114 161 226 193 246 247 251 201
Selling, General & Admin Expense		 18 46 51 55 65 68 76 71 70 72 50
Research & Development Expense		 19 57 83 59 97 158 117 175 178 167 90
Restructuring Charge		 - - - - - - - 0.00 0.00 12 61
Total Other Income / (Expense), net		 -38 0.01 -0.39 3.77 7.18 19 0.64 5.52 16 14 -0.05
Interest Expense		 - - - - - - - - - 2.19 6.17
Interest & Investment Income		 -0.14 0.06 -0.98 3.45 7.31 2.61 0.61 5.52 18 16 8.31
Other Income / (Expense), net		 -37 -0.06 0.59 0.33 -0.14 16 0.04 0.00 -1.60 -0.00 -2.19
Other Gains / (Losses), net		 - - - - - - 0.64 - - - -0.05
Basic Earnings per Share		 ($28.55) ($3.02) ($2.98) ($2.33) ($2.68) ($1.98) ($2.85) ($3.21) ($2.02) ($2.88) ($1.80)
Weighted Average Basic Shares Outstanding		 2.57M 32.22M 40.32M 47.10M 49.98M 58.61M 67.62M 68.66M 75.97M 82.34M 88.75M
Diluted Earnings per Share		 ($28.55) ($3.02) ($2.98) ($2.33) ($2.68) ($1.98) ($2.85) ($3.21) ($2.02) ($2.88) ($1.80)
Weighted Average Diluted Shares Outstanding		 2.57M 32.22M 40.32M 47.10M 49.98M 58.61M 67.62M 68.66M 75.97M 82.34M 88.75M
Weighted Average Basic & Diluted Shares Outstanding		 2.57M 32.22M 40.32M 47.10M 49.98M 58.61M 68.52M 68.97M 81.81M 82.98M 97.87M

Quarterly Income Statements for Editas Medicine

This table shows Editas Medicine's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -19 -62 -68 -62 -45 -76 -53 -25 -5.62 -25 -18
Consolidated Net Income / (Loss)		 -19 -62 -68 -62 -45 -76 -53 -25 -5.62 -25 -18
Net Income / (Loss) Continuing Operations		 -19 -62 -68 -62 -45 -76 -53 -25 -5.75 -25 -18
Total Pre-Tax Income 		-19 -62 -68 -62 -45 -76 -53 -25 -5.62 -25 -18
Total Operating Income		 -24 -67 -72 -66 -47 -76 -52 -25 -7.76 -25 -19
Total Gross Profit		 60 1.14 0.00 0.00 -1.71 0.00 3.58 7.54 29 0.00 12
Total Revenue		 60 1.14 0.00 0.00 -1.71 0.00 3.58 7.54 29 0.00 12
Operating Revenue		 60 1.14 0.00 0.00 -1.71 - 3.58 7.54 29 - 12
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 84 68 72 66 45 76 55 32 37 25 30
Selling, General & Admin Expense		 14 19 18 18 16 13 13 12 11 10 12
Research & Development Expense		 70 49 54 48 16 22 16 20 32 15 20
Restructuring Charge		 - 0.00 0.00 0.00 - 41 26 0.00 -6.26 0.00 -1.34
Total Other Income / (Expense), net		 5.09 5.04 4.30 3.53 1.20 0.08 -1.69 -0.57 2.14 0.02 0.32
Interest Expense		 - 0.00 0.00 0.00 - 2.22 2.02 2.40 -0.46 1.07 1.06
Interest & Investment Income		 5.10 5.04 4.30 3.53 1.20 2.72 2.09 1.83 1.68 1.21 1.37
Other Income / (Expense), net		 -0.01 0.01 -0.00 -0.01 -0.00 -0.43 -1.76 -0.00 -0.01 -0.11 0.02
Basic Earnings per Share		 ($0.20) ($0.76) ($0.82) ($0.75) ($0.55) ($0.92) ($0.63) ($0.28) $0.03 ($0.26) ($0.15)
Weighted Average Basic Shares Outstanding		 75.97M 81.94M 82.31M 82.49M 82.34M 83.06M 84.41M 90.09M 88.75M 97.88M 119.29M
Diluted Earnings per Share		 ($0.20) ($0.76) ($0.82) ($0.75) ($0.55) ($0.92) ($0.63) ($0.28) $0.03 ($0.26) ($0.15)
Weighted Average Diluted Shares Outstanding		 75.97M 81.94M 82.31M 82.49M 82.34M 83.06M 84.41M 90.09M 88.75M 97.88M 119.29M
Weighted Average Basic & Diluted Shares Outstanding		 81.81M 82.24M 82.48M 82.55M 82.98M 83.71M 89.92M 97.62M 97.87M 97.91M 153.58M

Annual Cash Flow Statements for Editas Medicine

This table details how cash moves in and out of Editas Medicine's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 133 43 -39 -12 103 -96 64 -62 -18 7.89 14
Net Cash From Operating Activities		 -5.44 -50 -9.42 -46 -41 -180 -164 -177 -132 -210 -165
Net Cash From Continuing Operating Activities		 -5.44 -50 -9.42 -46 -41 -180 -164 -177 -132 -210 -165
Net Income / (Loss) Continuing Operations		 -73 -97 -120 -110 -134 -116 -193 -220 -153 -237 -160
Consolidated Net Income / (Loss)		 -73 -97 -120 -110 -134 -116 -193 -220 -153 -237 -160
Depreciation Expense		 0.47 1.20 2.68 3.25 2.83 3.96 5.05 6.34 6.06 5.81 5.28
Non-Cash Adjustments To Reconcile Net Income		 41 28 38 34 24 34 43 29 24 17 18
Changes in Operating Assets and Liabilities, net		 26 18 71 27 66 -102 -21 8.08 -4.15 3.83 -29
Net Cash From Investing Activities		 -1.43 -3.47 -184 -53 12 -141 -54 114 -3.73 162 139
Net Cash From Continuing Investing Activities		 -1.43 -3.47 -184 -53 12 -141 -54 114 -3.73 162 139
Purchase of Property, Plant & Equipment		 -1.43 -3.49 -2.06 -4.75 -6.17 -7.16 -7.98 -4.12 -4.72 -8.83 -0.61
Purchase of Investments		 - - -375 -459 -342 -458 -409 -315 -259 -86 0.00
Sale of Property, Plant & Equipment		 - 0.02 0.02 0.04 0.10 0.01 0.00 0.02 0.00 0.00 0.27
Sale and/or Maturity of Investments		 - - 194 411 361 325 362 433 260 257 139
Net Cash From Financing Activities		 139 97 155 87 132 224 282 1.28 118 56 40
Net Cash From Continuing Financing Activities		 139 97 155 87 132 224 282 1.28 118 56 40
Repayment of Debt		 -2.08 -0.56 -1.36 -0.86 - - - - - 0.00 -2.87
Issuance of Common Equity		 0.01 97 154 77 117 205 251 0.98 118 0.59 43
Other Financing Activities, net		 - 0.23 1.76 10 15 20 31 0.31 0.04 55 0.07
Cash Interest Paid		 0.09 - - - - - - - - 0.00 2.13

Quarterly Cash Flow Statements for Editas Medicine

This table details how cash moves in and out of Editas Medicine's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 41 -54 -4.79 31 36 7.15 -0.15 26 -19 -23 58
Net Cash From Operating Activities		 -22 -50 -57 -53 -51 -48 -50 -31 -36 -23 -30
Net Cash From Continuing Operating Activities		 -22 -50 -57 -53 -51 -48 -50 -31 -36 -23 -30
Net Income / (Loss) Continuing Operations		 -19 -62 -68 -62 -45 -76 -53 -25 -5.62 -25 -18
Consolidated Net Income / (Loss)		 -19 -62 -68 -62 -45 -76 -53 -25 -5.62 -25 -18
Depreciation Expense		 1.47 1.41 1.42 1.60 1.38 1.92 1.83 0.72 0.81 0.48 0.42
Amortization Expense		 -2.10 -1.72 -1.88 -1.33 -0.87 -0.58 -0.26 -0.06 - 0.00 -0.14
Non-Cash Adjustments To Reconcile Net Income		 5.54 7.43 3.65 5.95 5.94 7.21 3.86 4.22 0.65 -1.81 3.13
Changes in Operating Assets and Liabilities, net		 -8.27 4.96 7.36 3.33 -12 20 -2.39 -11 -33 3.25 -15
Net Cash From Investing Activities		 63 -4.75 52 84 31 56 43 40 0.06 0.06 -30
Net Cash From Continuing Investing Activities		 63 -4.75 52 84 31 56 43 40 0.06 0.06 -30
Purchase of Property, Plant & Equipment		 -1.31 -1.87 -3.49 -2.92 -0.54 -0.11 - -0.43 -0.06 -0.09 -0.11
Net Cash From Financing Activities		 0.51 0.19 0.32 - 56 -1.44 7.41 17 17 0.00 118
Net Cash From Continuing Financing Activities		 0.51 0.19 0.32 - 56 -1.44 7.41 17 17 0.00 118
Issuance of Common Equity		 0.48 0.00 0.32 - 0.27 1.44 7.41 17 17 0.00 117

Annual Balance Sheets for Editas Medicine

This table presents Editas Medicine's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 149 229 373 420 509 573 677 514 499 342 187
Total Current Assets		 145 187 332 375 464 419 507 357 341 289 164
Cash & Equivalents		 143 185 147 135 238 140 204 142 124 132 147
Short-Term Investments		 - - 183 234 219 262 296 203 199 138 0.00
Accounts Receivable		 1.02 0.09 0.68 0.03 0.42 6.05 0.27 5.15 10 16 15
Prepaid Expenses		 0.79 1.77 2.38 5.79 6.29 11 7.20 7.34 7.53 3.14 2.07
Plant, Property, & Equipment, net		 2.13 40 39 40 11 14 17 16 12 14 3.54
Total Noncurrent Assets		 2.25 1.62 1.62 5.38 34 139 153 142 146 38 19
Other Noncurrent Operating Assets		 2.25 1.62 1.62 5.38 34 30 33 49 42 38 19
Total Liabilities & Shareholders' Equity		 149 229 373 420 509 573 677 514 499 342 187
Total Liabilities		 33 95 165 184 246 179 124 154 150 207 159
Total Current Liabilities		 6.93 33 37 36 60 58 47 60 63 77 46
Short-Term Debt		 0.00 10 7.50 - - - - - 0.00 5.00 5.00
Accounts Payable		 1.38 4.64 4.02 5.33 5.84 6.41 5.05 9.51 8.27 5.49 2.61
Accrued Expenses		 5.54 17 11 13 22 24 20 31 35 46 33
Current Deferred Revenue		 - 0.26 13 16 24 21 11 8.22 8.22 6.22 0.00
Other Current Liabilities		 0.00 0.75 0.90 2.05 8.49 6.81 10 11 12 15 6.03
Total Noncurrent Liabilities		 26 61 128 148 186 121 77 94 87 130 113
Long-Term Debt		 - - - - - - - - 0.00 52 54
Noncurrent Deferred Revenue		 25 26 95 116 163 74 61 61 61 54 45
Other Noncurrent Operating Liabilities		 0.32 0.40 0.32 0.29 23 47 16 33 26 23 15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - - - - - 0.00 0.00
Total Equity & Noncontrolling Interests		 -83 135 208 236 262 394 554 361 349 134 27
Total Preferred & Common Equity		 -83 135 208 236 262 394 554 361 349 134 27
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -83 135 208 236 262 394 554 361 349 134 27
Common Stock		 5.23 320 514 652 812 1,059 1,412 1,442 1,580 1,602 1,656
Retained Earnings		 -88 -186 -306 -416 -549 -665 -858 -1,078 -1,231 -1,468 -1,629
Accumulated Other Comprehensive Income / (Loss)		 - - -0.08 -0.03 0.11 -0.05 -0.49 -3.60 0.20 0.27 0.00

Quarterly Balance Sheets for Editas Medicine

This table presents Editas Medicine's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 505 440 385 328 264 211 202 149 237
Total Current Assets		 359 306 286 271 225 183 177 128 218
Cash & Equivalents		 83 69 64 96 139 139 166 124 182
Short-Term Investments		 267 227 215 169 82 40 0.00 - 30
Accounts Receivable		 2.42 0.25 0.24 0.13 0.51 0.59 8.13 2.59 2.73
Prepaid Expenses		 6.56 9.14 7.00 5.93 3.37 3.71 3.11 1.83 3.70
Plant, Property, & Equipment, net		 12 13 14 15 8.18 4.58 4.29 2.88 2.57
Total Noncurrent Assets		 134 122 84 41 31 23 21 18 17
Other Noncurrent Operating Assets		 38 41 45 41 31 23 21 18 17
Total Liabilities & Shareholders' Equity		 505 440 385 328 264 211 202 149 237
Total Liabilities		 144 146 153 152 201 191 188 145 132
Total Current Liabilities		 59 66 74 72 73 66 62 40 68
Short-Term Debt		 - - - - 5.00 5.00 5.00 7.50 7.50
Accounts Payable		 10 7.97 14 12 5.47 6.72 3.16 4.33 4.74
Accrued Expenses		 30 31 28 29 47 48 48 21 17
Current Deferred Revenue		 8.22 15 15 15 2.00 0.00 0.00 - 32
Other Current Liabilities		 9.69 12 18 16 13 6.15 6.09 6.70 6.51
Total Noncurrent Liabilities		 86 79 78 80 128 125 127 105 64
Long-Term Debt		 - - - - 50 52 54 47 48
Noncurrent Deferred Revenue		 61 54 54 54 54 54 54 45 4.00
Other Noncurrent Operating Liabilities		 25 25 24 25 24 20 18 13 11
Commitments & Contingencies		 - - - - - - - - 0.00
Total Equity & Noncontrolling Interests		 360 294 232 176 62 19 13 4.41 105
Total Preferred & Common Equity		 360 294 232 176 62 19 13 4.41 105
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 360 294 232 176 62 19 13 4.41 105
Common Stock		 1,574 1,588 1,593 1,598 1,607 1,617 1,636 1,658 1,777
Retained Earnings		 -1,212 -1,293 -1,361 -1,423 -1,545 -1,598 -1,623 -1,653 -1,672
Accumulated Other Comprehensive Income / (Loss)		 -1.45 -0.33 -0.44 0.52 0.09 0.02 0.00 0.00 -0.01

Annual Metrics And Ratios for Editas Medicine

This table displays calculated financial ratios and metrics derived from Editas Medicine's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 36,655,936.00 42,119,611.00 47,810,190.00 51,302,885.00 62,334,218.00 68,398,540.00 68,762,960.00 81,673,688.00 - 97,618,660.00
DEI Adjusted Shares Outstanding		 0.00 36,655,936.00 42,119,611.00 47,810,190.00 51,302,885.00 62,334,218.00 68,398,540.00 68,762,960.00 81,673,688.00 - 97,618,660.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.65 -2.86 -2.30 -2.61 -1.86 -2.81 -3.21 -1.88 - -1.64
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 271.58% 126.80% -100.00% 0.00% 341.93% -100.00% 0.00% 296.32% -100.00% 0.00%
EBITDA Growth		 -435.69% -32.87% -21.47% 5.59% -25.50% 17.08% -62.62% -18.21% 23.05% -48.13% 36.04%
EBIT Growth		 -432.98% -33.66% -22.73% 4.98% -24.39% 15.94% -62.85% -17.01% 24.41% -47.06% 35.42%
NOPAT Growth		 -177.54% -175.23% -23.40% 5.17% -23.91% 4.32% -43.24% -16.98% 25.12% -48.45% 36.29%
Net Income Growth		 -432.70% -33.31% -23.81% 8.62% -21.64% 13.29% -65.98% -14.51% 30.49% -54.74% 32.49%
EPS Growth		 -129.13% 89.42% 1.32% 21.81% -15.02% 26.12% -43.94% -12.63% 37.07% -42.57% 37.50%
Operating Cash Flow Growth		 37.11% -823.13% 81.26% -385.37% 11.02% -342.21% 8.92% -8.27% 25.47% -59.09% 21.42%
Free Cash Flow Firm Growth		 0.00% -5,446.90% 89.36% -528.48% 92.73% -3,857.55% -9.49% 21.04% 20.76% -50.02% 26.29%
Invested Capital Growth		 0.00% 78.70% -1,325.77% -25.27% -93.97% 39.30% 43.92% -15.72% -1.76% -0.21% 22.32%
Revenue Q/Q Growth		 0.00% 1.78% 25.27% -100.00% 216.85% 20.77% -100.00% 393.64% 148.61% -100.00% 305.77%
EBITDA Q/Q Growth		 0.00% -37.28% 2.45% 8.49% -10.61% -24.98% 11.03% -11.37% 18.21% -9.35% 20.32%
EBIT Q/Q Growth		 0.00% -37.30% 2.22% 8.15% -10.29% -24.47% 9.86% -10.70% 18.77% -9.90% 19.32%
NOPAT Q/Q Growth		 0.00% -37.70% 2.08% 8.22% -10.31% -24.40% 11.16% -10.70% 18.92% -9.90% 19.53%
Net Income Q/Q Growth		 0.00% -37.97% 2.58% 9.20% -10.51% -27.10% 9.86% -9.60% 21.46% -12.59% 19.90%
EPS Q/Q Growth		 0.00% 18.60% 7.74% 12.08% -8.50% -14.45% 11.49% -9.18% 25.19% -13.83% 24.37%
Operating Cash Flow Q/Q Growth		 0.00% -7.02% -576.81% 36.61% 49.40% -82.18% 3.26% -4.53% 13.16% -15.69% 8.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -1,206.63% 34.50% 90.84% -73.75% -2.77% 1.11% 5.45% -12.26% 4.47%
Invested Capital Q/Q Growth		 0.00% -339.15% 4.88% -24.93% -58.78% -18.02% 5.65% -20.36% 9.21% 12.58% 34.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -4,437.45% -1,586.70% -849.82% 0.00% -673.27% -126.33% 0.00% -1,117.78% -217.02% 0.00% -387.27%
Operating Margin		 -2,167.71% -1,605.62% -873.64% 0.00% -686.39% -148.61% 0.00% -1,146.26% -216.56% 0.00% -394.89%
EBIT Margin		 -4,466.36% -1,606.56% -869.36% 0.00% -687.05% -130.69% 0.00% -1,146.26% -218.61% 0.00% -400.29%
Profit (Net Income) Margin		 -4,475.14% -1,605.53% -876.49% 0.00% -651.43% -127.82% 0.00% -1,118.26% -196.13% 0.00% -395.01%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.20% 99.94% 100.82% 96.96% 94.82% 97.80% 99.69% 97.56% 89.71% 94.40% 98.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -62.41% -77.31% -70.22% -49.50% -53.65% -35.36% -40.65% -48.22% -43.17% -98.10% -198.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -48.71% -51.38% -39.62% 0.00% -30.36% -21.93% 0.00% -37.92% -33.70% 0.00% -61.42%
Return on Assets (ROA)		 -48.81% -51.35% -39.95% 0.00% -28.79% -21.45% 0.00% -36.99% -30.24% 0.00% -60.61%
Return on Common Equity (ROCE)		 44.41% -15.83% -70.22% -49.50% -53.65% -35.36% -40.65% -48.22% -43.17% -98.10% -198.14%
Return on Equity Simple (ROE_SIMPLE)		 87.71% -72.20% -57.83% -46.56% -50.96% -29.47% -34.77% -61.12% -43.89% -176.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -68 -84 -80 -99 -94 -135 -158 -118 -176 -112
NOPAT Margin		 -1,517.40% -1,123.93% -611.55% 0.00% -480.47% -104.03% 0.00% -802.38% -151.59% 0.00% -276.42%
Net Nonoperating Expense Percent (NNEP)		 -67.30% -20.57% -16.98% -9.71% -8.85% -4.46% -10.13% -11.78% -8.05% -19.16% -31.98%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -43.85% -33.92% -91.71% -130.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,110.80% 764.28% 367.88% 0.00% 314.43% 74.48% 0.00% 358.69% 89.16% 0.00% 123.16%
R&D to Revenue		 1,156.91% 941.33% 605.76% 0.00% 471.96% 174.13% 0.00% 887.57% 227.40% 0.00% 222.00%
Operating Expenses to Revenue		 2,267.71% 1,705.62% 973.64% 0.00% 786.39% 248.61% 0.00% 1,246.26% 316.56% 0.00% 494.89%
Earnings before Interest and Taxes (EBIT)		 -73 -97 -119 -113 -141 -119 -193 -226 -171 -251 -162
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -72 -96 -117 -110 -138 -115 -186 -220 -170 -251 -157
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.42 6.22 4.61 5.79 11.10 3.28 1.69 2.37 0.78 7.33
Price to Tangible Book Value (P/TBV)		 0.00 4.42 6.22 4.61 5.79 11.10 3.28 1.69 2.37 0.78 7.33
Price to Revenue (P/Rev)		 0.00 98.29 94.28 0.00 73.99 48.17 0.00 30.94 10.59 0.00 4.94
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 75.12 73.29 0.00 51.72 42.53 0.00 8.75 5.12 0.00 2.77
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.34 0.20 0.14 0.00 0.00 0.00 0.00 0.00 0.43 2.15
Long-Term Debt to Equity		 0.00 0.26 0.16 0.14 0.00 0.00 0.00 0.00 0.00 0.39 1.96
Financial Leverage		 -1.23 -1.13 -1.25 -1.41 -1.59 -1.48 -1.19 -1.16 -1.22 -1.32 -1.86
Leverage Ratio		 1.28 1.51 1.76 1.79 1.86 1.65 1.32 1.30 1.43 1.74 3.27
Compound Leverage Factor		 1.28 1.50 1.77 1.73 1.77 1.61 1.32 1.27 1.28 1.64 3.23
Debt to Total Capital		 0.00% 25.09% 16.44% 12.07% 0.00% 0.00% 0.00% 0.00% 0.00% 29.96% 68.23%
Short-Term Debt to Total Capital		 0.00% 5.56% 3.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.61% 5.82%
Long-Term Debt to Total Capital		 0.00% 19.53% 13.43% 12.07% 0.00% 0.00% 0.00% 0.00% 0.00% 27.35% 62.41%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 171.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -71.16% 74.91% 83.56% 87.93% 100.00% 100.00% 100.00% 100.00% 100.00% 70.04% 31.77%
Debt to EBITDA		 0.00 -0.47 -0.35 -0.29 0.00 0.00 0.00 0.00 0.00 -0.23 -0.37
Net Debt to EBITDA		 0.00 1.46 2.47 3.06 0.00 0.00 0.00 0.00 0.00 0.85 0.56
Long-Term Debt to EBITDA		 0.00 -0.37 -0.29 -0.29 0.00 0.00 0.00 0.00 0.00 -0.21 -0.34
Debt to NOPAT		 0.00 -0.66 -0.49 -0.41 0.00 0.00 0.00 0.00 0.00 -0.33 -0.52
Net Debt to NOPAT		 0.00 2.06 3.43 4.23 0.00 0.00 0.00 0.00 0.00 1.21 0.79
Long-Term Debt to NOPAT		 0.00 -0.52 -0.40 -0.41 0.00 0.00 0.00 0.00 0.00 -0.30 -0.48
Altman Z-Score		 0.00 2.07 3.49 2.23 2.27 13.25 6.90 -1.27 -0.45 -7.40 -13.36
Noncontrolling Interest Sharing Ratio		 171.16% 79.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 20.94 5.66 9.05 10.44 7.74 7.20 10.82 5.94 5.39 3.75 3.54
Quick Ratio		 20.82 5.60 8.99 10.28 7.63 7.01 10.67 5.81 5.27 3.71 3.50
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.66 -89 -9.45 -59 -4.32 -171 -187 -148 -117 -176 -129
Operating Cash Flow to CapEx		 -380.36% -1,446.76% -460.71% -968.98% -670.55% -2,515.29% -2,053.44% -4,325.59% -2,800.97% -2,382.55% -48,887.87%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20.98
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.78
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.83
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.03 0.05 0.00 0.04 0.17 0.00 0.03 0.15 0.00 0.15
Accounts Receivable Turnover		 1.60 10.94 35.80 0.00 91.66 28.06 0.00 7.28 10.19 0.00 2.58
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.76 0.28 0.34 0.00 0.80 7.29 0.00 1.21 5.66 0.00 4.49
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 228.32 33.38 10.20 0.00 3.98 13.01 0.00 50.11 35.82 0.00 141.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 228.32 33.38 10.20 0.00 3.98 13.01 0.00 50.11 35.82 0.00 141.61
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -26 -5.62 -80 -100 -195 -118 -66 -77 -78 -78 -61
Invested Capital Turnover		 -0.12 -0.38 -0.32 0.00 -0.14 -0.58 0.00 -0.28 -1.01 0.00 -0.58
Increase / (Decrease) in Invested Capital		 -26 21 -75 -20 -94 77 52 -10 -1.35 -0.17 17
Enterprise Value (EV)		 0.00 455 1,006 751 1,062 3,858 1,196 173 400 -108 112
Market Capitalization		 0.00 595 1,294 1,088 1,519 4,370 1,816 610 827 105 200
Book Value per Share		 ($32.38) $3.67 $4.94 $4.94 $5.12 $6.31 $8.09 $5.25 $4.27 $1.63 $0.28
Tangible Book Value per Share		 ($32.38) $3.67 $4.94 $4.94 $5.12 $6.31 $8.09 $5.25 $4.27 $1.63 $0.28
Total Capital		 117 180 249 269 262 394 554 361 349 192 86
Total Debt		 0.00 45 41 32 0.00 0.00 0.00 0.00 0.00 57 59
Total Long-Term Debt		 0.00 35 33 32 0.00 0.00 0.00 0.00 0.00 52 54
Net Debt		 -143 -140 -288 -337 -457 -512 -620 -437 -427 -212 -88
Capital Expenditures (CapEx)		 1.43 3.47 2.04 4.72 6.07 7.15 7.98 4.10 4.72 8.83 0.34
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.12 -21 -26 -30 -53 -41 -39 -48 -45 -53 -24
Debt-free Net Working Capital (DFNWC)		 138 164 303 339 404 361 460 297 278 217 123
Net Working Capital (NWC)		 138 154 295 339 404 361 460 297 278 212 118
Net Nonoperating Expense (NNE)		 48 29 36 30 35 22 57 62 35 61 48
Net Nonoperating Obligations (NNO)		 -143 -140 -288 -337 -457 -512 -620 -437 -427 -212 -88
Total Depreciation and Amortization (D&A)		 0.47 1.20 2.68 3.25 2.83 3.96 6.71 5.61 1.24 0.02 5.28
Debt-free, Cash-free Net Working Capital to Revenue		 -314.30% -350.62% -190.46% 0.00% -259.41% -45.44% 0.00% -241.63% -58.24% 0.00% -59.22%
Debt-free Net Working Capital to Revenue		 8,475.14% 2,711.05% 2,207.11% 0.00% 1,967.18% 397.74% 0.00% 1,504.89% 355.35% 0.00% 302.69%
Net Working Capital to Revenue		 8,475.14% 2,545.85% 2,152.48% 0.00% 1,967.18% 397.74% 0.00% 1,504.89% 355.35% 0.00% 290.35%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($28.55) ($3.02) ($2.98) ($2.33) ($2.68) ($1.98) ($2.85) ($3.21) ($2.02) ($2.88) ($1.80)
Adjusted Weighted Average Basic Shares Outstanding		 2.57M 36.68M 46.88M 49.09M 54.88M 67.36M 67.62M 68.66M 75.97M 82.34M 88.75M
Adjusted Diluted Earnings per Share		 ($28.55) ($3.02) ($2.98) ($2.33) ($2.68) ($1.98) ($2.83) ($3.21) ($2.02) ($2.88) ($1.80)
Adjusted Weighted Average Diluted Shares Outstanding		 2.57M 36.68M 46.88M 49.09M 54.88M 67.36M 67.62M 68.66M 75.97M 82.34M 88.75M
Adjusted Basic & Diluted Earnings per Share		 ($28.55) ($3.02) ($2.98) ($2.33) ($2.68) ($1.98) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.57M 32.22M 40.32M 47.10M 49.98M 58.61M 68.52M 68.97M 81.81M 82.98M 97.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -68 -84 -80 -99 -94 -135 -158 -118 -167 -70
Normalized NOPAT Margin		 -1,517.40% -1,123.93% -611.55% 0.00% -480.47% -104.03% 0.00% -802.38% -151.59% 0.00% -171.61%
Pre Tax Income Margin		 -4,475.14% -1,605.53% -876.49% 0.00% -651.43% -127.82% 0.00% -1,118.26% -196.13% 0.00% -395.01%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.28
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.15
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -26.34
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.21
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Editas Medicine

This table displays calculated financial ratios and metrics derived from Editas Medicine's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 81,673,688.00 81,673,688.00 82,237,974.00 82,476,436.00 - 82,976,284.00 83,712,859.00 89,920,164.00 97,618,660.00 97,871,999.00 97,906,282.00
DEI Adjusted Shares Outstanding		 81,673,688.00 81,673,688.00 82,237,974.00 82,476,436.00 - 82,976,284.00 83,712,859.00 89,920,164.00 97,618,660.00 97,871,999.00 97,906,282.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.23 -0.76 -0.82 -0.75 - -0.92 -0.64 -0.28 -0.06 -0.26 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 349.81% -88.48% -100.00% -100.00% -102.85% -100.00% 0.00% 0.00% 2,690.22% 0.00% 232.31%
EBITDA Growth		 60.54% -30.17% -66.96% -31.07% -87.23% -11.83% 28.52% 63.47% 84.62% 67.27% 64.69%
EBIT Growth		 62.21% -27.48% -63.04% -30.92% -94.34% -14.34% 25.87% 62.62% 83.35% 67.21% 65.22%
NOPAT Growth		 62.23% -31.46% -63.07% -30.91% -94.43% -13.69% 28.31% 62.62% 83.36% 67.17% 64.00%
Net Income Growth		 68.93% -26.34% -67.80% -38.03% -140.52% -22.82% 21.26% 59.58% 87.62% 67.17% 65.76%
EPS Growth		 77.27% -7.04% -46.43% -36.36% -175.00% -21.05% 23.17% 62.67% 105.45% 71.74% 76.19%
Operating Cash Flow Growth		 47.39% -39.43% -47.41% -48.31% -128.25% 4.16% 12.00% 41.35% 28.32% 51.75% 41.11%
Free Cash Flow Firm Growth		 54.62% -873.40% -240.77% -229.74% -110.33% 35.02% 55.30% 68.18% 29.48% -79.37% -229.35%
Invested Capital Growth		 -1.76% 2.29% -7.72% -4.07% -0.21% -26.21% -18.94% -4.10% 22.32% 37.90% 50.68%
Revenue Q/Q Growth		 1,025.36% -98.11% -100.00% 0.00% -2,901.64% 100.00% 0.00% 110.82% 289.75% -100.00% 0.00%
EBITDA Q/Q Growth		 50.67% -173.40% -7.54% 9.63% 29.53% -66.44% 31.27% 53.81% 70.89% -254.18% 25.86%
EBIT Q/Q Growth		 52.20% -179.38% -7.34% 8.67% 29.05% -64.37% 30.40% 53.94% 68.39% -223.66% 26.19%
NOPAT Q/Q Growth		 52.23% -179.56% -7.33% 8.67% 29.05% -63.47% 32.32% 52.37% 68.41% -222.41% 25.79%
Net Income Q/Q Growth		 58.08% -228.23% -9.13% 8.09% 26.95% -67.61% 30.04% 52.82% 77.62% -344.52% 27.03%
EPS Q/Q Growth		 63.64% -280.00% -7.89% 8.54% 26.67% -67.27% 31.52% 55.56% 110.71% -966.67% 42.31%
Operating Cash Flow Q/Q Growth		 37.28% -124.24% -14.42% 7.84% 3.47% 5.84% -5.05% 38.57% -17.97% 36.62% -28.22%
Free Cash Flow Firm Q/Q Growth		 -19.79% -216.47% 9.57% 3.82% 23.59% 2.23% 37.79% 31.54% -69.35% -148.69% -14.23%
Invested Capital Q/Q Growth		 9.21% -5.56% -4.76% -3.66% 12.58% -32.94% 1.27% 9.27% 34.76% -6.27% 21.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.00%
EBITDA Margin		 -40.99% -5,928.81% 0.00% 0.00% 0.00% 0.00% -1,445.64% -316.72% -23.66% 0.00% -153.60%
Operating Margin		 -39.91% -5,902.29% 0.00% 0.00% 0.00% 0.00% -1,440.58% -325.44% -26.38% 0.00% -156.05%
EBIT Margin		 -39.93% -5,901.76% 0.00% 0.00% 0.00% 0.00% -1,489.71% -325.45% -26.40% 0.00% -155.90%
Profit (Net Income) Margin		 -31.43% -5,458.15% 0.00% 0.00% 0.00% 0.00% -1,487.84% -332.98% -19.12% 0.00% -153.32%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 78.72% 92.48% 94.02% 94.62% 97.42% 99.35% 99.87% 102.31% 72.42% 99.47% 98.34%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -43.17% -54.30% -61.23% -78.56% -98.10% -140.82% -188.58% -211.37% -198.14% -326.07% -118.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -6.16% -905.79% 0.00% 0.00% 0.00% 0.00% -12.23% -12.28% -4.05% 0.00% -33.99%
Return on Assets (ROA)		 -4.85% -837.71% 0.00% 0.00% 0.00% 0.00% -12.21% -12.56% -2.93% 0.00% -33.43%
Return on Common Equity (ROCE)		 -43.17% -54.30% -61.23% -78.56% -98.10% -140.82% -188.58% -211.37% -198.14% -326.07% -118.82%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -56.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -47 -50 -46 -33 -53 -36 -17 -5.43 -18 -13
NOPAT Margin		 -27.93% -4,131.60% 0.00% 0.00% 0.00% 0.00% -1,008.41% -227.81% -18.46% 0.00% -109.23%
Net Nonoperating Expense Percent (NNEP)		 -0.49% -3.87% -4.33% -4.55% -4.00% -8.39% -7.79% -4.27% -0.13% -6.36% -3.77%
Return On Investment Capital (ROIC_SIMPLE)		 -4.81% -15.93% -21.69% -26.17% -17.01% -45.57% -47.56% -23.69% -6.32% -29.62% -8.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 24.07% 1,703.88% 0.00% 0.00% 0.00% 0.00% 359.39% 163.28% 38.62% 0.00% 97.59%
R&D to Revenue		 115.83% 4,298.41% 0.00% 0.00% 0.00% 0.00% 452.24% 262.16% 109.06% 0.00% 169.72%
Operating Expenses to Revenue		 139.91% 6,002.29% 0.00% 0.00% 0.00% 0.00% 1,540.58% 425.44% 126.38% 0.00% 256.05%
Earnings before Interest and Taxes (EBIT)		 -24 -67 -72 -66 -47 -77 -53 -25 -7.76 -25 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -67 -72 -65 -46 -75 -52 -24 -6.96 -25 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.37 2.06 1.66 1.60 0.78 1.54 9.60 23.19 7.33 54.84 3.01
Price to Tangible Book Value (P/TBV)		 2.37 2.06 1.66 1.60 0.78 1.54 9.60 23.19 7.33 54.84 3.01
Price to Revenue (P/Rev)		 10.59 8.73 5.77 4.60 0.00 0.00 75.39 31.25 4.94 5.97 6.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.12 3.30 0.99 0.26 0.00 0.00 25.52 20.57 2.77 4.26 3.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.43 0.87 2.95 4.39 2.15 12.40 0.53
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.39 0.79 2.69 4.02 1.96 10.70 0.46
Financial Leverage		 -1.22 -1.27 -1.26 -1.33 -1.32 -1.52 -1.75 -1.97 -1.86 -3.52 -2.23
Leverage Ratio		 1.43 1.48 1.47 1.55 1.74 1.97 2.37 2.80 3.27 6.18 3.60
Compound Leverage Factor		 1.12 1.37 1.38 1.47 1.69 1.96 2.37 2.86 2.37 6.15 3.54
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 29.96% 46.65% 74.70% 81.45% 68.23% 92.54% 34.62%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 2.61% 4.27% 6.59% 6.89% 5.82% 12.69% 4.66%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 27.35% 42.38% 68.11% 74.56% 62.41% 79.85% 29.96%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 70.04% 53.35% 25.30% 18.55% 31.77% 7.46% 65.38%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.23 -0.21 -0.24 -0.30 -0.37 -0.51 -0.76
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.85 0.65 0.51 0.54 0.56 0.65 2.12
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.21 -0.19 -0.22 -0.27 -0.34 -0.44 -0.66
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.33 -0.30 -0.34 -0.42 -0.52 -0.72 -1.05
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 1.21 0.91 0.73 0.77 0.79 0.91 2.94
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.30 -0.27 -0.31 -0.39 -0.48 -0.62 -0.91
Altman Z-Score		 0.52 -1.31 -3.23 -4.72 -5.42 -8.19 -10.20 -9.93 -10.63 -14.07 -7.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.39 4.60 3.85 3.75 3.75 3.08 2.77 2.86 3.54 3.22 3.19
Quick Ratio		 5.27 4.46 3.76 3.67 3.71 3.03 2.72 2.81 3.50 3.17 3.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -49 -44 -42 -32 -32 -20 -14 -23 -57 -65
Operating Cash Flow to CapEx		 -1,701.61% -2,665.53% -1,633.14% -1,800.34% -9,400.37% -41,928.95% 0.00% -7,123.09% 0.00% 0.00% -27,894.34%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -14.32 -9.77 -5.63 0.00 -53.08 -61.27
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -21.57 -24.86 -12.86 0.00 -21.51 -27.87
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -21.62 -24.86 -13.04 0.00 -21.45 -27.97
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.15 0.15 0.14 0.15 0.00 0.00 0.01 0.04 0.15 0.20 0.22
Accounts Receivable Turnover		 10.19 285.04 52.59 48.03 0.00 0.00 5.87 2.42 2.58 26.13 29.48
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 5.66 5.24 4.93 4.54 0.00 0.00 0.26 1.01 4.49 7.32 13.66
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 35.82 1.28 6.94 7.60 0.00 0.00 62.15 150.88 141.61 13.97 12.38
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 35.82 1.28 6.94 7.60 0.00 0.00 62.15 150.88 141.61 13.97 12.38
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -78 -82 -86 -89 -78 -104 -103 -93 -61 -65 -51
Invested Capital Turnover		 -1.01 -0.83 -0.80 -0.70 0.00 0.00 -0.03 -0.11 -0.58 -0.48 -0.64
Increase / (Decrease) in Invested Capital		 -1.35 1.93 -6.18 -3.50 -0.17 -22 -16 -3.67 17 39 52
Enterprise Value (EV)		 400 229 66 16 -108 -70 62 205 112 173 161
Market Capitalization		 827 606 384 281 105 96 184 312 200 242 317
Book Value per Share		 $4.27 $3.59 $2.82 $2.13 $1.63 $0.75 $0.23 $0.15 $0.28 $0.05 $1.08
Tangible Book Value per Share		 $4.27 $3.59 $2.82 $2.13 $1.63 $0.75 $0.23 $0.15 $0.28 $0.05 $1.08
Total Capital		 349 294 232 176 192 117 76 73 86 59 161
Total Debt		 0.00 0.00 0.00 0.00 57 55 57 59 59 55 56
Total Long-Term Debt		 0.00 0.00 0.00 0.00 52 50 52 54 54 47 48
Net Debt		 -427 -377 -318 -265 -212 -166 -122 -107 -88 -69 -156
Capital Expenditures (CapEx)		 1.31 1.87 3.49 2.92 0.54 0.11 0.00 0.43 -0.06 -0.06 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -45 -57 -67 -66 -53 -64 -57 -46 -24 -28 -55
Debt-free Net Working Capital (DFNWC)		 278 239 212 199 217 157 122 120 123 96 157
Net Working Capital (NWC)		 278 239 212 199 212 152 117 115 118 88 150
Net Nonoperating Expense (NNE)		 2.10 15 17 16 13 23 17 7.93 0.19 7.48 5.24
Net Nonoperating Obligations (NNO)		 -427 -377 -318 -265 -212 -166 -122 -107 -88 -69 -156
Total Depreciation and Amortization (D&A)		 -0.64 -0.31 -0.46 0.27 0.51 1.33 1.58 0.66 0.81 0.48 0.27
Debt-free, Cash-free Net Working Capital to Revenue		 -58.24% -82.27% -100.82% -108.36% 0.00% 0.00% -2,318.54% -455.94% -59.22% -68.76% -111.63%
Debt-free Net Working Capital to Revenue		 355.35% 344.44% 318.77% 324.90% 0.00% 0.00% 4,988.09% 1,202.86% 302.69% 236.39% 321.78%
Net Working Capital to Revenue		 355.35% 344.44% 318.77% 324.90% 0.00% 0.00% 4,783.42% 1,152.79% 290.35% 217.89% 306.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.76) ($0.82) ($0.75) ($0.55) ($0.92) ($0.63) ($0.28) $0.03 ($0.26) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 75.97M 81.94M 82.31M 82.49M 82.34M 83.06M 84.41M 90.09M 88.75M 97.88M 119.29M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.76) ($0.82) ($0.75) ($0.55) ($0.92) ($0.63) ($0.28) $0.03 ($0.26) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 75.97M 81.94M 82.31M 82.49M 82.34M 83.06M 84.41M 90.09M 88.75M 97.88M 119.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 81.81M 82.24M 82.48M 82.55M 82.98M 83.71M 89.92M 97.62M 97.87M 97.91M 153.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -47 -50 -46 -33 -25 -18 -17 -9.81 -18 -14
Normalized NOPAT Margin		 -27.93% -4,131.60% 0.00% 0.00% 0.00% 0.00% -498.14% -227.81% -33.37% 0.00% -117.12%
Pre Tax Income Margin		 -31.43% -5,458.15% 0.00% 0.00% 0.00% 0.00% -1,487.84% -332.98% -19.12% 0.00% -153.32%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -34.56 -26.39 -10.23 0.00 -23.43 -17.47
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.06 -17.86 -7.16 0.00 -16.33 -12.24
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -34.61 -26.39 -10.41 0.00 -23.37 -17.57
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -24.11 -17.86 -7.34 0.00 -16.27 -12.34
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Editas Medicine’s financial profile improved in the second quarter of 2026, but the company remains loss-making and dependent on external funding. Revenue was $11.9 million, compared with no revenue in the first quarter and $7.5 million in the third quarter of 2025. Revenue has been volatile, including $29.4 million in the fourth quarter of 2025 and $60.0 million in the fourth quarter of 2023, which suggests that collaboration or milestone-related revenue is not yet consistent.

Operating expenses totaled $30.4 million in Q2 2026, down sharply from $76.2 million in Q1 2025 and $71.9 million in Q2 2024. Research and development spending was $20.2 million, while selling, general and administrative costs were $11.6 million. As a result, the quarterly net loss narrowed to $18.2 million, or $0.15 per share, from losses of $76.1 million in Q1 2025 and $67.6 million in Q2 2024. However, Editas still generated a $29.6 million operating cash outflow during the quarter.

Liquidity improved substantially during Q2 because the company raised $117.5 million through common-equity issuance. Cash and equivalents totaled $181.8 million, and short-term investments added $29.8 million, providing approximately $211.6 million of cash and near-cash resources. At the same time, the equity raise increased dilution risk, and total debt stood at approximately $55.7 million. Based on the latest quarterly operating cash burn, the reported liquidity could support several quarters of operations, although that runway will depend on future research spending, revenue receipts and additional financing.

  • Operating losses are narrowing: The Q2 2026 net loss of $18.2 million was the company’s smallest reported loss among the recent quarters supplied, helped by lower research, administrative and restructuring expenses.
  • Cost structure has improved: Total operating expenses declined to $30.4 million from more than $70 million in several 2024 and early-2025 quarters, indicating the restructuring program is reducing ongoing spending.
  • Liquidity was replenished: Cash, equivalents and short-term investments reached approximately $211.6 million at June 30, 2026, up from $123.6 million of cash at the end of Q1 2026.
  • Balance-sheet equity recovered: Total equity increased to $105.3 million from just $4.4 million in Q1 2026, while total liabilities declined from $188.3 million in Q3 2025 to $132.1 million in Q2 2026.
  • Revenue returned in Q2: The company recorded $11.9 million of revenue after reporting no revenue in Q1 2026, providing some support for operations and indicating continued potential for collaboration-related revenue.
  • Revenue remains unpredictable: Quarterly revenue has ranged from zero to $29.4 million in the recent period, so investors should not assume that the Q2 revenue level represents a stable recurring run rate.
  • Deferred revenue remains significant: Current and noncurrent deferred revenue totaled approximately $36.3 million, which may support future reported revenue but will be recognized over time and does not represent unrestricted cash available for new spending.
  • Operations continue to consume cash: Operating cash flow was negative $29.6 million in Q2 2026 following outflows of $23.1 million in Q1 2026 and $36.4 million in Q4 2025.
  • The company remains unprofitable: Editas has reported recurring quarterly net losses, and retained earnings were negative $1.67 billion at June 30, 2026.
  • Equity financing created substantial dilution: The $117.5 million common-stock issuance helped fund the business but coincided with weighted-average basic shares rising to 119.3 million in Q2 2026 from 97.9 million in Q1, increasing the ownership dilution burden for existing shareholders.
10/13/26 03:35 PM ETAI Generated. May Contain Errors.

Editas Medicine Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Editas Medicine's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Editas Medicine's net income appears to be on a downward trend, with a most recent value of -$160.06 million in 2025, falling from -$72.90 million in 2015. The previous period was -$237.09 million in 2024. See where experts think Editas Medicine is headed by visiting Editas Medicine's forecast page.

Editas Medicine's total operating income in 2025 was -$160.01 million, based on the following breakdown:
  • Total Gross Profit: $40.52 million
  • Total Operating Expenses: $200.53 million

Over the last 10 years, Editas Medicine's total revenue changed from $1.63 million in 2015 to $40.52 million in 2025, a change of 2,387.4%.

In the past 11 quarters, Editas Medicine's cash and equivalents has ranged from $64.44 million in Q2 2024 to $181.82 million in Q2 2026, and is currently $181.82 million as of their latest financial filing in Q2 2026.

Editas Medicine had total debt of $58.61 million at the end of 2025, a 2.0% increase from 2024, and none in 2015.

Over the last 10 years, Editas Medicine's book value per share changed from -32.38 in 2015 to 0.28 in 2025.


Related Companies

Financial statements for NASDAQ:EDIT last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel